Pharmaceutical Industry: The Road to Industrial Upgrading by Industry Transfer
The development of India's pharmaceutical industry has presented us with a vivid road to industrial upgrading. We have extracted four key factors for industrial upgrading and believe that cooperation is the optimal strategy for China's pharmaceutical companies to realize formulation exports, whether through cooperation. The model (formulation OEM, transfer of production of the product, co-development) deals with indirect export preparation or through cooperation to solve the problem of sales channels in the independent export of preparations. It further clarified the business models at different stages in the process of moving to a global generic pharmaceutical company: cooperation model, ANDA, challenge patent/authorized generics, and NDA model. The vanguard of industrial upgrading: The road to transformation is gradually approaching, and the outbreak of performance is just around the corner. Hisun Pharmaceutical has stepped into the harvest period of “industrial upgrading†and is expected to bring about explosive growth in performance; Huahai Pharmaceutical Co., Ltd. will undertake large-scale cooperation and customization; Hengrui Medicine will upgrade to innovative drugs and advance the generic drug FDA certification in the United States. In order to achieve industrial upgrading, Hapriy has made global heparin API leaders unique and world-leading processes and high-quality products, and continues to share the high growth brought by order transfer. The core outsourcing business of the industry chain is characterized by "double height", and high quality A shares are worth looking forward to. The case of Chinese pharmaceutical company WuXiKangDe, which mainly engages in international CRO business, and India's Dishman company, which mainly engages in international CRAMS business, show that the medical outsourcing model presents double-high characteristics: high profitability and high growth. The case of Dr. Reddys and RanbaxyLab, representing the entire history of India's industrial upgrading, shows that every major development in the generics business has led to a significant increase in share price and valuation, while the high valuation in the transition process has quickly been expected to be highly profitable. Digested, the holder is profitable. There is no doubt that domestic high-quality pharmaceutical companies that are undertaking or will undertake large-scale industrial transfer are worth looking forward to.
1. We have Good location
We`re located in the well known Ningbo International Port.
2. We`re Well-experienced
Tropical Group has many factories in the world, has 48 years experience in seafood export
3. We`re High quality assurance
Our company has passed HACCP, BRC, MSC, FDA, KOSHER and the other certifications.
4. We can do Best price
We are an industry and trade integration enterprise, which producing, packing and selling all by ourselves, greatly reducing the price difference caused by broker
5. We have Rich products
We have our own design department and R & D team, which can design personalized products according to customers' requirements.
6. We can do On-time delivery
Our products are exported to the United States, South America, Africa, Europe, Russia and other countries and regions. Company exports amounted to more than US$60 million in last year, enjoys high reputation in the aquatic products industry.
Canned Mackerel,Canned Fish Mackerel,Canned Mackerel Fillet In Oil,Chunk Light Mackerel In Water Tropical Food Manufacturing (Ningbo) Co., Ltd. , https://www.tropical-food.com